Igenica: Igenica, MedImmune enter into oncology research agreement
Igenica Biotherapeutics has entered an oncology research agreement with AstraZeneca's global biologics research and development arm MedImmune to evaluate the potential of antibody-drug conjugates (ADCs), targeting surface antigen in leukaemia (SAIL)....
Read full article »
Co-Founder
Robert Schreiber
Igenica engages in discovery and development of antibody-based therapeutics for the treatment of cancer.
Read more